Last reviewed · How we verify
NCT03846596: SEPSIROS
Flow Cytometry Analysis of the Reactive Oxygen Species in Immature Granulocytes in Septic Patient
trial testing Additional blood tube in Sepsis in 34 participants. Terminated before completion.
10 March 2020
Quick facts
| Lead sponsor | University Hospital, Limoges |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 34 |
| Start date | 26 March 2019 |
| Primary completion | 10 March 2020 |
| Estimated completion | 10 March 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Additional blood tube — full drug profile →
Conditions studied
- Sepsis — all drugs for Sepsis →
Sponsor
University Hospital, Limoges
Who can join
18 and older, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. Early during sepsis course, immature neutrophils could be found in the bloodstream and may be less efficient than mature neutrophils in reactive oxygen species (ROS) production. ROS induce an oxidative stress for bacteria which can protect through the SOS response. The main objective is to evaluate the level of ROS produced in the early steps of sepsis by the immature neutrophils.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Phagosomal granulocytic ROS in septic patients induce the bacterial SOS response.
Chollet S, Hernandez Padilla AC, Daix T, Gaschet M, et al · · 2024 · PMID 38799552 · DOI 10.1016/j.isci.2024.109825
Verify or expand the search:
- PubMed search for NCT03846596
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other University Hospital, Limoges trials
Trials by the same sponsor.
- NCT07407101 — Impact of Filtration on Autologous Serum Eye Drops · NA · not yet recruiting
- NCT07406425 — Evaluation of Efficacy of Coconut Oil Mouth Care for Non-autonomous Hospitalised Elderly People. · NA · not yet recruiting
- NCT07436780 — B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP · not yet recruiting
- NCT07331298 — Apparent Diffusion Coefficient of the Intervertebral Disc in Children: Pilot Study · not yet recruiting
- NCT07019818 — Esmolol Versus Sufentanil on the Quality of Post-cholecystectomy Recovery Laparoscopic Anaesthesia With Orotracheal Intu · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03846596 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Limoges
- Last refreshed: 8 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03846596.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing